While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the ...

France-based Adcytherix has completed a Series A funding round, raising €105m ($122m) earmarked for expediting the ADC ...

EMD Serono has partnered the Trump administration to expand access to the company’s in vitro fertilisation (IVF) therapies.

The AAM’s Giuseppe Randazzo warns that the generics business could become unsustainable in the future if the market dynamics ...

Nabla Bio has entered a new multi-year research collaboration with Takeda to advance the AI-driven design of protein ...

Tubulis has completed a Series C, securing €308m ($361m) to be directed towards advancing clinical development of its ADC ...

With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ...

Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.

The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen ...

"Meanwhile, Goldman Sachs led by value but faced close competition from JP Morgan. The investment banks had their own notable ...

A consortium led by Nordic Capital and Permira has raised its bid, though certain shareholder stances remain firm.

Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another ...